Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Locati LD, et al. Among authors: elisei r. Eur J Cancer. 2019 Sep;118:35-40. doi: 10.1016/j.ejca.2019.05.031. Epub 2019 Jul 9. Eur J Cancer. 2019. PMID: 31299580
Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma.
Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, Pacini F, Santini F, Elisei R. Castagna MG, et al. Among authors: elisei r. J Clin Endocrinol Metab. 2005 Jul;90(7):4047-50. doi: 10.1210/jc.2005-0534. Epub 2005 May 3. J Clin Endocrinol Metab. 2005. PMID: 15870133
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R. Fugazzola L, et al. Among authors: elisei r. Endocr Relat Cancer. 2006 Jun;13(2):455-64. doi: 10.1677/erc.1.01086. Endocr Relat Cancer. 2006. PMID: 16728573
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Schlumberger MJ, et al. Among authors: elisei r. J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29. J Clin Oncol. 2009. PMID: 19564535 Clinical Trial.
367 results